Department of Health and Human Services February 21, 2007 – Federal Register Recent Federal Regulation Documents
Results 1 - 30 of 30
Proposed Collection; Comment Request; Customer Satisfaction With Educational Programs and Products of the National Cancer Institute
In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
Prospective Grant of Exclusive License: The Use of Adenovirus Vectors for the Development of Vaccines Against Human Immunodeficiency Virus and Other Infectious Agents
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive patent license to practice the inventions embodied in Patent Cooperation Treaty Application No. PCT/US02/27592 filed August 29, 2002 and United States National Stage Application Serial No. 10/487,974 filed February 27, 2004, entitled ``New Adenovirus Type 7 Vectors'' [HHS Reference No. E-236-2001/0], and United States Patent Application Serial No. 11/282,319 filed November 17, 2005, entitled ``Improved Replication-Competent Adenovirus Vectors'' [HHS Reference No. E-203-2004/0], to PaxVax, Inc., which has offices in Menlo Park, CA. The patent rights in these inventions have been assigned and/or exclusively licensed to the Government of the United States of America. The prospective exclusive license territory may be the United States of America, and the field of use may be limited to the development of vaccines against human immunodeficiency virus, human papillomavirus, influenza, malaria, and tuberculosis.
Proposed Collection Comment Request; Monitoring and Evaluation of the NIDA Goes Back to School National Dissemination Campaign; Revision
In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collection of information, the National Institute on Drug Abuse (NIDA), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. We are publishing a revised version of the notice that we published in the Federal Register on January 30, 2006 (72 FR 4273-4274) to reflect a correction in the data presented in Table A. In the previous notice, we inadvertently calculated the burden totals on the basis of 400 subjects for a single year. We should have calculated the burden totals on the basis of 400 subjects per each of three study years. Today's notice corrects that error.
Control of Communicable Diseases; Restrictions on African Rodents, Prairie Dogs, and Certain Other Animals
The Food and Drug Administration (FDA) is reopening the comment period for the interim final rule on the capture, transport, sale, barter, exchange, distribution, and release of African rodents, prairie dogs, and certain other animals, which was published in the Federal Register of November 4, 2003 (68 FR 62353). FDA is taking this action because it is adding new information, primarily in the form of peer-reviewed scientific literature, to the administrative record. FDA is reopening the comment period for 30 days for the sole purpose of inviting public comments on the information being added to the administrative record.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
